Trial · NCT03228914
Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
NCT03228914, Phase 4, Completed, The University of Texas Health Science Center, Houston; results first posted 2021-01-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery. Trials, record NCT03228914. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03228914
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
- NCT number
- NCT03228914
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 20 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Endoscopic Sinus Surgery, Nasal Polyps
- Interventions
- Oxymetazoline, Epinephrine
- First posted
- 2017-07-25
- Last updated
- 2021-01-13
- Results first posted
- 2021-01-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale | during surgery approximately 2-3 hours | The minimum Boezaart Grading Scale score of 0 indicates no bleeding (cadaveric conditions), and the maximum score of 5 indicates severe bleeding (constant suctioning required). |
| Secondary | Amount of Blood Loss in mL | immediately at the completion of surgery (surgery lasts about 2-3 hours, and the suctioning stops immediately following the completion of the case) | The secondary endpoint will be to compare the amount of blood loss use after the use of epinephrine or Oxymetazoline. This will be done by subtracting the amount of irrigation used from the volume collected in the suction canisters to estimate blood loss. The Neptune 2 Waste Management System (NWMS, Stryker, Kalamazoo, Michigan), a closed suction system that digitally measures the amount of fluid suctioned will be used for more accurate measuring of fluid suctioned. Surgery lasts about 2-3 hours, and the suctioning stops immediately following the completion of the case. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale | during surgery approximately 2-3 hours | For each participant who started the study, oxymetazoline was administered to one side of the nasal cavity and epinephrine was administered to the other side of the nasal cavity. Each participant has two sides of the nasal cavity, and each participant received both oxymetazoline and epinephrine, one drug per side. | score on a scale | MEAN |
| SECONDARY | Amount of Blood Loss in mL | immediately at the completion of surgery (surgery lasts about 2-3 hours, and the suctioning stops immediately following the completion of the case) | Data was not collected for this measure. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale | Oxymetazoline | 3 | Standard Deviation 0.19 | score on a scale | |
| Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale | Epinephrine | 2.55 | Standard Deviation 0.15 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Oxymetazoline | 20 | 20 |
| Overall Study | STARTED | Epinephrine | 20 | 20 |
| Overall Study | COMPLETED | Oxymetazoline | 20 | 20 |
| Overall Study | COMPLETED | Epinephrine | 20 | 20 |
| Overall Study | NOT COMPLETED | Oxymetazoline | 0 | 0 |
| Overall Study | NOT COMPLETED | Epinephrine | 0 | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Oxymetazoline | 0 | 20 |
| Total, all-cause mortality | Epinephrine | 0 | 20 |
| Total, other adverse events | Oxymetazoline | 0 | 20 |
| Total, other adverse events | Epinephrine | 0 | 20 |
| Total, serious adverse events | Oxymetazoline | 0 | 20 |
| Total, serious adverse events | Epinephrine | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Oxymetazoline vs Epinephrine: deaths from any cause | Trial comparisons |
| Oxymetazoline vs Epinephrine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03228914
GET https://conductscience.org/api/trials/v1/NCT03228914/registered